Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-30 @ 12:00 AM
Study NCT ID:
NCT07464535
Status:
COMPLETED
Last Update Posted:
2026-03-11
First Post:
2026-03-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects
Sponsor:
Tonix Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-18
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-30
Completion Date Type:
ACTUAL
First Submit Date:
2026-03-06
First Submit QC Date:
None
Study First Post Date:
2026-03-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-06
Last Update Post Date:
2026-03-11
Last Update Post Date Type:
ACTUAL